Ketones

Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis

Retrieved on: 
Thursday, March 4, 2021
Steroids, Organic compounds, Drugs, Androstanes, Ketones, Enones, Testosterone, Testosterone undecanoate, Hydroxyprogesterone caproate

The results were featured in a paper entitled "Treatment Potential ofLPCN 1144 onLiver Health andMetabolic Regulation inaNonGenomic, High Fat Diet Induced NASH Rabbit Model" (Comeglio et al), published in the Journal of Endocrinological Investigation ( https://doi.org/10.1007/s40618-021-01522-7 ).

Key Points: 
  • The results were featured in a paper entitled "Treatment Potential ofLPCN 1144 onLiver Health andMetabolic Regulation inaNonGenomic, High Fat Diet Induced NASH Rabbit Model" (Comeglio et al), published in the Journal of Endocrinological Investigation ( https://doi.org/10.1007/s40618-021-01522-7 ).
  • Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies.
  • Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107.
  • TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing.

Lipocine Announces Presentations on TLANDO™ at ENDO 2021 Conference

Retrieved on: 
Wednesday, March 3, 2021
Steroids, Organic compounds, Androstanes, Chemical compounds, Enones, Estrogens, GABAA receptor positive allosteric modulators, Ketones, Testosterone undecanoate, Testosterone, Hydroxyprogesterone caproate

Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107.

Key Points: 
  • Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107.
  • TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing.
  • In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points.
  • Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

Ehave Inc. Reaches Milestone; Ketamine IV Therapy Provider KetaDASH to Launch Beta in Second Quarter 2021

Retrieved on: 
Friday, February 26, 2021
Drugs, Psychoactive drugs, Neurochemistry, Dissociative drugs, Ketones, Amines, Nicotinic antagonists, Sedatives, Ketamine, Digital therapeutics

MIAMI, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the Company), a provider of digital therapeutics for the psychedelic and mental health sectors, announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology.

Key Points: 
  • MIAMI, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the Company), a provider of digital therapeutics for the psychedelic and mental health sectors, announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology.
  • KetaDASH is a personalized mental care platform designed to instantly connect patients with highly skilled nurses to provide ketamine therapy at home under expert supervision.
  • Ehave has also secured an umbrella policy to cover liability and malpractice insurance on each home delivery service.
  • The KetaDASH platform allows licensed ketamine clinics and patients who have been prescribed ketamine by a physician to administer the treatment at home intravenously.

Lipocine to Present at Two Upcoming Investor Conferences

Retrieved on: 
Friday, February 26, 2021
Steroids, Drugs, Organic compounds, Androstanes, Ketones, Enones, Testosterone, Veterinary drugs, Testosterone undecanoate, Hydroxyprogesterone caproate

The webcasts of these presentations will also be available on Lipocine's corporate website under "Events & Presentations" in the Investors section.

Key Points: 
  • The webcasts of these presentations will also be available on Lipocine's corporate website under "Events & Presentations" in the Investors section.
  • Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies.
  • Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107.
  • TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing.

PureTech Founded Entity Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia

Retrieved on: 
Thursday, February 25, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Digestive diseases, Medical specialties, Clinical medicine, Antiemetics, Imidazoles, Ketones, Ondansetron, Constipation, Schizophrenia, KarXT, Schizophrenia, Karuna, PureTech Health

The double-blind, placebo-controlled, five-week inpatient EMERGENT-1 Phase 2 trial enrolled 182 adults with an acute exacerbation of schizophrenia.

Key Points: 
  • The double-blind, placebo-controlled, five-week inpatient EMERGENT-1 Phase 2 trial enrolled 182 adults with an acute exacerbation of schizophrenia.
  • Results published in NEJM also include data for pre-specified secondary outcome measures.
  • Rates of nausea, vomiting, and dry mouth decreased over the course of the trial, while rates of constipation remained essentially constant.
  • Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.

Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia

Retrieved on: 
Wednesday, February 24, 2021
Mental health, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Drugs, Digestive diseases, Clinical medicine, Antiemetics, Imidazoles, Ketones, Ondansetron, Schizophrenia, Constipation, KarXT, Schizophrenia, Karuna

The double-blind, placebo-controlled, five-week inpatient EMERGENT-1 Phase 2 trial enrolled 182 adults with an acute exacerbation of schizophrenia.

Key Points: 
  • The double-blind, placebo-controlled, five-week inpatient EMERGENT-1 Phase 2 trial enrolled 182 adults with an acute exacerbation of schizophrenia.
  • Rates of nausea, vomiting, and dry mouth decreased over the course of the trial, while rates of constipation remained essentially constant.
  • With the help of a dedicated treatment team, it is possible for people with schizophrenia to live full lives.
  • Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.

Antares Pharma to Present at Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, February 24, 2021
Drugs, Steroids, Health care, Androstanes, Dosage forms, Ketones, Testosterone enanthate, Transgender hormone therapy, Teva Pharmaceuticals, Sumatriptan, Testosterone, Ferring Pharmaceuticals

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.

Key Points: 
  • Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.
  • Antares Pharmas FDA-approved products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
  • The Company also markets NOCDURNA (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.
  • Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.

Pear Therapeutics Announces Publication of Economic Analysis Showing Cost-Effectiveness of reSET-O® in Treating Opioid Use Disorder

Retrieved on: 
Tuesday, February 23, 2021
Biotechnology, FDA, Pharmaceutical, Health, Substance dependence, Opioid use disorder, Psychoactive drugs, Opioid, Morphinans, Chemical compounds, Ketones, Articles, Pharmacy

Pear Therapeutics, Inc. , today announced publication of new analysis demonstrating the cost-effectiveness of reSET-O, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD).

Key Points: 
  • Pear Therapeutics, Inc. , today announced publication of new analysis demonstrating the cost-effectiveness of reSET-O, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD).
  • In addition to clinical value, these results emphasize the limited economic risk of reSET-O as an adjunct to TAU.
  • The full paper, Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder, is available online by clicking here .
  • In recent years, OUD has been responsible for approximately two out of every three deaths related to substance use disorder (SUD)5.

Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19

Retrieved on: 
Monday, February 22, 2021
Drugs, Medical emergencies, Medicine, Clinical medicine, Morphinans, Opioid antagonists, Ketones, Substance abuse, Naloxone, Food and Drug Administration, Opioid overdose, Opioid

The clearance to proceed follows the submission of an IND application to FDA and a Pre-IND meeting.

Key Points: 
  • The clearance to proceed follows the submission of an IND application to FDA and a Pre-IND meeting.
  • In addition, Tempol has been shown to decrease platelet aggregation, a problem observed in many COVID-19 patients.
  • If this trial is successful, we would likely petition the FDA to consider Emergency Use Authorization for Tempol as a therapeutic treatment for COVID-19.
  • Adamis naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review.

Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate

Retrieved on: 
Wednesday, February 17, 2021
Drugs, Psychoactive drugs, Morphinans, Medical emergencies, Morphine, Opioids, Ketones, Naloxone, Drug overdose, Heroin, Opioid epidemic in the United States, New Jersey Opioid Antidote Prescription Bill

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation(Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHIhigh dose naloxone injection product candidate, intended for the treatment of opioid overdose, was allowed by the U.S. Patent and Trademark Office.

Key Points: 
  • SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation(Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHIhigh dose naloxone injection product candidate, intended for the treatment of opioid overdose, was allowed by the U.S. Patent and Trademark Office.
  • The company believes this patent should protect and strengthen the existing intellectual property associated with the product candidate.
  • Concomitant with the rise of overdoses caused by synthetic opioids, deaths have risen despite increased availability of the current naloxone product.
  • Adamis naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review.